Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14556020 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL14106729 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL21539004 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL22697521 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24825613 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL10038938 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24824212 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL23266122 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL20713594 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18158169 | 1.00 | L3MBTL1 (0.49) | L3MBTL1LGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135574-A1 | ASCAROSIDE DERIVATIVES AND METHODS OF USE | HOLOCLARA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135574-A1 | ASCAROSIDE DERIVATIVES AND METHODS OF USE | HOLOCLARA, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135574-A1 | ASCAROSIDE DERIVATIVES AND METHODS OF USE | TLR4, TLR7, MYD88 | L3MBTL1 4802/4885LGALS1 153/4885LGALS3 181/4885 |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | SI, FABP2, ALPI | L3MBTL1 3978/4885LGALS1 195/4885LGALS3 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.